This text is a result of machine translation.
Pure Global: The International Engine of Medical Technology Globalization
As a pioneer in international regulatory management and clinical solutions, Pure Global has evolved into an indispensable partner for medical technology companies. Through its outstanding data technology, seasoned industry expert team, and transnational capabilities, Pure Global empowers its partners to achieve global growth. Presently, Pure Global's services span more than 25 countries and regions, offering tailored solutions for the entire lifecycle of medical devices.
Sep 28, 2023 09:30 AM
Aimeike signs distribution cooperation framework agreement with South Korea huons BP
Baijiu plate strength, mouth cellar line exceeds 10%
AMEC: the capital increase and acquisition of part of the equity of hoons biopharma in South Korea have been completed
The investment banking business was strictly supervised, and seven securities companies received fines
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
The first batch of "Mao" concept achievements were released, with a year-on-year growth of more than 50%
The medical and American plate rose sharply
AMEC: the net profit in the first half of the year was 425 million yuan, a year-on-year increase of 188.86%
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
Aimike's reply to the letter of concern: after obtaining the equity of huons bio, it will not have a significant adverse impact on the company's production and operation
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
Apr 23, 2024 02:21 PM